1. NVALT25/ELDAPT
Elderly with locally advanced Lung cancer: Deciding through geriatric Assessment on the oPtimal Treatment strategy

2. Objective
The primary objective of the project is to compare concurrent and sequential RCHT with respect to quality-adjusted survival (QAS) of elderly patients (≥75 years) with stage III NSCLC.
Secondary objectives:
To perform a geriatric assessment in stage III NSCLC patients to distinguish patients fit enough to undergo intensified treatment and to develop a reliable and clinically applicable geriatric screening instrument to guide treatment decisions in stage III NSCLC;
To compare concurrent and sequential RCHT with respect to overall and progression free survival, overall and lung-cancer specific quality of life (QoL) and preservation of independence
To compare cost-effectiveness of sequential and concurrent RCHT for elderly patients with stage III NSCLC
To implement and disseminate the developed geriatric screening instrument in national and international guidelines

3. Study design: A multicentric randomized phase III trial comparing two treatment arms.
Inclusion consists of 2 parts. All registered patients will undergo the first part, consisting of a geriatric assessment to assess vulnerability. Based on this assessment, fit patients are selected for part II: the randomized clinical trial.
Study population: Patients with any subtype of NSCLC, primary UICC Stage III, age ≥ 75 years

4. Participating centres

5. Actives centers MUMC/MAASTRO clinic
- open for inclusion since juni 2016
- 2 patients included
Laurentius hospital
- open for inclusion since november 2016

6. Opening soon (Q1 2017) VieCuri Canisius-Wilhelmina Ziekenhuis LUMC
MC Haaglanden
Radboudumc

7. issues
Datamanagement
Bloed-biomarkers

8. Study team & info PI’s: Prof. dr. A. Dingemans – MUMC
Dr. J. van Loon – MAASTRO clinic
Dr. M. Janssen-Heijnen – VieCuri
Trial coordination:
Michelle Neuhof - DCM- MAASTRO clinic
More info:
password: kwfnvalt25